300702 天宇股份
已收盘 01-12 15:00:00
资讯
新帖
简况
天宇股份(300702.SZ)：阿帕他胺原料药通过CDE审评
智通财经 · 01-07
天宇股份(300702.SZ)：阿帕他胺原料药通过CDE审评
天宇股份（300702）披露变更签字注册会计师公告，1月6日股价下跌0.41%
证券之星 · 01-06
天宇股份（300702）披露变更签字注册会计师公告，1月6日股价下跌0.41%
天宇股份（300702）披露完成《公司章程》备案，12月23日股价上涨0.76%
证券之星 · 2025-12-23
天宇股份（300702）披露完成《公司章程》备案，12月23日股价上涨0.76%
天宇股份（300702）披露全资子公司药品获得批准，12月22日股价下跌1.54%
证券之星 · 2025-12-22
天宇股份（300702）披露全资子公司药品获得批准，12月22日股价下跌1.54%
天宇股份最新公告：全资子公司药品盐酸曲唑酮片获得批准
证券之星 · 2025-12-22
天宇股份最新公告：全资子公司药品盐酸曲唑酮片获得批准
天宇股份（300702）股东林洁质押190万股，占总股本0.55%
证券之星 · 2025-11-21
天宇股份（300702）股东林洁质押190万股，占总股本0.55%
天宇股份（300702）披露修订公司章程及部分管理制度议案获股东大会通过，11月18日股价上涨0.15%
证券之星 · 2025-11-18
天宇股份（300702）披露修订公司章程及部分管理制度议案获股东大会通过，11月18日股价上涨0.15%
11月14日天宇股份涨5.11%，信澳医药健康混合A基金重仓该股
证券之星 · 2025-11-14
11月14日天宇股份涨5.11%，信澳医药健康混合A基金重仓该股
【机构调研记录】明亚基金调研天宇股份
证券之星 · 2025-10-31
【机构调研记录】明亚基金调研天宇股份
天宇股份(300702)9月30日股东户数1.52万户，较上期减少8.06%
证券之星 · 2025-10-30
天宇股份(300702)9月30日股东户数1.52万户，较上期减少8.06%
图解天宇股份三季报：第三季度单季净利润同比增长123.90%
证券之星 · 2025-10-30
图解天宇股份三季报：第三季度单季净利润同比增长123.90%
天宇股份（300702）股东林洁质押760万股，占总股本2.18%
证券之星 · 2025-10-27
天宇股份（300702）股东林洁质押760万股，占总股本2.18%
10月15日天宇股份发布公告，股东减持344.49万股
证券之星 · 2025-10-15
10月15日天宇股份发布公告，股东减持344.49万股
天宇股份（300702）披露部分募集资金投资项目延期公告，9月29日股价下跌0.7%
证券之星 · 2025-09-29
天宇股份（300702）披露部分募集资金投资项目延期公告，9月29日股价下跌0.7%
9月24日天宇股份现1笔折价21.44%的大宗交易 合计成交4846.07万元
证券之星 · 2025-09-24
9月24日天宇股份现1笔折价21.44%的大宗交易 合计成交4846.07万元
天宇股份（300702）股东屠勇军质押1000万股，占总股本2.87%
证券之星 · 2025-09-15
天宇股份（300702）股东屠勇军质押1000万股，占总股本2.87%
天宇股份(300702.SZ)：坎地沙坦酯片完成药品注册
智通财经 · 2025-09-04
天宇股份(300702.SZ)：坎地沙坦酯片完成药品注册
9月1日天宇股份涨6.08%，兴业医疗保健混合A基金重仓该股
证券之星 · 2025-09-01
9月1日天宇股份涨6.08%，兴业医疗保健混合A基金重仓该股
天宇股份最新公告：子公司制剂产品首次获得美国FDA批准文号
证券之星 · 2025-08-29
天宇股份最新公告：子公司制剂产品首次获得美国FDA批准文号
【机构调研记录】凯石基金调研天宇股份
证券之星 · 2025-08-26
【机构调研记录】凯石基金调研天宇股份
加载更多
公司概况
公司名称：
浙江天宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-09-19
主营业务：
浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。
发行价格：
22.41
{"stockData":{"symbol":"300702","market":"SZ","secType":"STK","nameCN":"天宇股份","latestPrice":25.78,"timestamp":1768201416000,"preClose":25.45,"halted":0,"volume":3708616,"delay":0,"changeRate":0.013,"floatShares":211000000,"shares":348000000,"eps":0.5511,"marketStatus":"已收盘","change":0.33,"latestTime":"01-12 15:00:00","open":25.77,"high":26.28,"low":25.5,"amount":95257200,"amplitude":0.0306,"askPrice":25.78,"askSize":44,"bidPrice":25.7,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.5511,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":25.45,"symbolType":"stock","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":28,"lowLimit":22.91,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":347977159,"isCdr":false,"pbRate":2.38,"roa":"--","peRate":46.779169,"roe":"6.12%","epsLYR":0.16,"committee":-0.427992,"marketValue":8971000000,"turnoverRate":0.0176,"status":0,"floatMarketCap":5444000000},"requestUrl":"/m/hq/s/300702","defaultTab":"news","newsList":[{"id":"2601820078","title":"天宇股份(300702.SZ)：阿帕他胺原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2601820078","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601820078?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:58","pubTimestamp":1767772688,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天宇股份(300702.SZ)公告，公司全资子公司浙江京圣药业有限公司(“京圣药业”)阿帕他胺原料药于近日通过国家药品监督管理局药品审评中心(“CDE”)审评。阿帕他胺是一种用于治疗前列腺癌的非甾体类抗雄激素药物，通过抑制雄激素受体信号通路发挥作用，延缓疾病进展。它主要用于非转移性去势抵抗性前列腺癌(nmCRPC)和转移性去势敏感性前列腺癌(mCSPC)，需在医生指导下联合去势治疗使用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223083913.SGD","300702","BK0239","LU1223082196.USD","CDE","BK4017","LU1223082519.USD"],"gpt_icon":0},{"id":"2601481323","title":"天宇股份（300702）披露变更签字注册会计师公告，1月6日股价下跌0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601481323","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601481323?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:24","pubTimestamp":1767709466,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，天宇股份报收于24.58元，较前一交易日下跌0.41%，最新总市值为85.53亿元。该股当日开盘24.77元，最高24.77元，最低24.28元，成交额达6176.34万元，换手率为1.19%。公司近日发布公告称，因保持独立性需要，天健会计师事务所将公司2025年度财务报表及内部控制审计的签字注册会计师由金晨希变更为周小民，变更后由周小民和李翀共同担任。周小民自2000年起在天健会计师事务所工作，2002年取得注册会计师资格，近三年未因执业行为受过处罚。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2593416977","title":"天宇股份（300702）披露完成《公司章程》备案，12月23日股价上涨0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593416977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593416977?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:44","pubTimestamp":1766501069,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，天宇股份报收于23.91元，较前一交易日上涨0.76%，最新总市值为83.2亿元。该股当日开盘23.83元，最高23.99元，最低23.61元，成交额达3942.95万元，换手率为0.79%。公司近日发布公告称，已于近期完成《公司章程》的工商备案手续。此前，公司于2025年10月29日召开董事会及监事会会议，并于2025年11月18日召开2025年第三次临时股东大会，审议通过了修订《公司章程》的议案。具体内容可参见公司同日披露的《公司章程》文件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300041080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2593433029","title":"天宇股份（300702）披露全资子公司药品获得批准，12月22日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433029","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593433029?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:35","pubTimestamp":1766414146,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，天宇股份报收于23.73元，较前一交易日下跌1.54%，最新总市值为82.57亿元。该股当日开盘24.08元，最高24.15元，最低23.73元，成交额达4197.12万元，换手率为0.83%。公司近日发布公告称，其全资子公司浙江诺得药业有限公司收到国家药品监督管理局核准签发的盐酸曲唑酮片《药品注册证书》，药品批准文号为国药准字H20256265，有效期至2030年12月15日。该药品适用于抑郁症治疗，注册分类为化学药品3类。公司对该品种累计研发投入约617.34万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200035038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2593485145","title":"天宇股份最新公告：全资子公司药品盐酸曲唑酮片获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485145","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485145?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:45","pubTimestamp":1766396718,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称，公司全资子公司诺得药业收到国家药监局核准签发的盐酸曲唑酮片的《药品注册证书》。该药品适用于抑郁症的治疗，对伴有或不伴有焦虑的患者均有效。截至公告日，国内生产商另有9家企业。2024年该药品在国内销售额约5.96亿元。诺得药业累计研发投入约617.34万元。该药品获得批件后可在境内生产、销售，有望增加公司制剂业务收入，提升市场竞争力，对公司经营业绩产生积极影响。但药品未来生产、销售情况可能受市场环境变化等因素影响，盈利水平具有不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2585141541","title":"天宇股份（300702）股东林洁质押190万股，占总股本0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585141541","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585141541?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:35","pubTimestamp":1763721312,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份11月21日公开信息显示，股东林洁向招商证券股份有限公司合计质押190.0万股，占总股本0.55%。质押详情见下表：截止本公告日，股东林洁已累计质押股份2000.0万股，占其持股总数的16.39%，股东屠勇军已累计质押股份1530.0万股，占其持股总数的26.79%。天宇股份主营业务：化学原料药及中间体的研发、注册、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100029688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2584955550","title":"天宇股份（300702）披露修订公司章程及部分管理制度议案获股东大会通过，11月18日股价上涨0.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955550?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:25","pubTimestamp":1763475922,"startTime":"0","endTime":"0","summary":"近日，浙江天宇药业股份有限公司召开2025年第三次临时股东大会，审议通过了《关于修订〈公司章程〉的议案》及《关于修订及制定公司部分管理制度的议案》。公告显示，上述议案采用现场与网络投票相结合的方式进行表决，《关于修订〈公司章程〉的议案》及部分子议案作为特别决议事项，已获出席会议股东所持有效表决权股份总数的2/3以上通过，会议表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2583575142","title":"11月14日天宇股份涨5.11%，信澳医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583575142","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583575142?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:37","pubTimestamp":1763109448,"startTime":"0","endTime":"0","summary":"证券之星消息，11月14日天宇股份涨5.11%，收盘报27.37元，换手率3.85%，成交量8.14万手，成交额2.21亿元。重仓天宇股份的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为38.08。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳医药健康混合A。该公募基金现任基金经理为李点典。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400025882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2579107727","title":"【机构调研记录】明亚基金调研天宇股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2579107727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579107727?lang=zh_cn&edition=full","pubTime":"2025-10-31 08:07","pubTimestamp":1761869231,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月30日披露的机构调研信息，明亚基金近期对1家上市公司进行了调研，相关名单如下：1）天宇股份 调研纪要：2025年制剂收入2.9亿元，展望2026年将迈入关键收获期，多个产品进入放量阶段，集采、零售及线上渠道协同发展。明亚基金成立于2019年，截至目前，资产管理规模2.71亿元，排名197/211；资产管理规模2.71亿元，排名170/211；管理公募基金数8只，排名157/211；旗下公募基金经理2人，排名177/211。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100011820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2579478113","title":"天宇股份(300702)9月30日股东户数1.52万户，较上期减少8.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579478113","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579478113?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:47","pubTimestamp":1761817625,"startTime":"0","endTime":"0","summary":"证券之星消息，近日天宇股份披露，截至2025年9月30日公司股东户数为1.52万户，较6月30日减少1335.0户，减幅为8.06%。在化学制药行业个股中，天宇股份股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.43万户。从股价来看，2025年6月30日至2025年9月30日，天宇股份区间涨幅为10.92%，在此期间股东户数减少1335.0户，减幅为8.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000034434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2579180698","title":"图解天宇股份三季报：第三季度单季净利润同比增长123.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579180698","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579180698?lang=zh_cn&edition=full","pubTime":"2025-10-30 03:24","pubTimestamp":1761765850,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份2025年三季报显示，前三季度公司主营收入22.87亿元，同比上升18.36%；归母净利润2.21亿元，同比上升159.57%；扣非净利润2.1亿元，同比上升130.13%；其中2025年第三季度，公司单季度主营收入7.2亿元，同比上升7.91%；单季度归母净利润7142.11万元，同比上升123.9%；单季度扣非净利润6881.97万元，同比上升141.18%；负债率43.32%，投资收益-18.24万元，财务费用2428.62万元，毛利率39.14%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000003271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702"],"gpt_icon":0},{"id":"2578501648","title":"天宇股份（300702）股东林洁质押760万股，占总股本2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578501648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578501648?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:19","pubTimestamp":1761563957,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份10月27日公开信息显示，股东林洁向招商证券股份有限公司合计质押760.0万股，占总股本2.18%。质押详情见下表：截止本公告日，股东林洁已累计质押股份2173.6万股，占其持股总数的17.81%，股东屠勇军已累计质押股份1530.0万股，占其持股总数的26.79%。天宇股份主营业务：化学原料药及中间体的研发、注册、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700029980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2575068781","title":"10月15日天宇股份发布公告，股东减持344.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2575068781","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575068781?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:01","pubTimestamp":1760529684,"startTime":"0","endTime":"0","summary":"证券之星消息，10月15日天宇股份发布公告《天宇股份:关于控股股东、实际控制人之一致行动人减持股份触及1%整数倍暨减持计划实施完成的公告》，其股东屠善增于2025年10月10日至2025年10月15日间合计减持344.49万股，占公司目前总股本的0.9901%，变动期间该股股价下跌4.44%，截止10月15日收盘报24.54元。股东增减持详情见下表：根据天宇股份2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500034679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2571433749","title":"天宇股份（300702）披露部分募集资金投资项目延期公告，9月29日股价下跌0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571433749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571433749?lang=zh_cn&edition=full","pubTime":"2025-09-29 22:43","pubTimestamp":1759156994,"startTime":"0","endTime":"0","summary":"截至2025年9月29日收盘，天宇股份报收于25.51元，较前一交易日下跌0.7%，最新总市值为88.77亿元。该股当日开盘25.67元，最高25.78元，最低25.06元，成交额达5349.4万元，换手率为1.0%。公司近日发布公告称，浙江天宇药业股份有限公司第五届监事会第十三次会议于2025年9月29日以现场结合通讯方式召开，会议审议通过《关于部分募集资金投资项目延期的议案》。表决结果为同意3票，反对0票，弃权0票，议案获通过。备查文件为经与会监事签字的会议决议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900035714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2569774186","title":"9月24日天宇股份现1笔折价21.44%的大宗交易 合计成交4846.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569774186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569774186?lang=zh_cn&edition=full","pubTime":"2025-09-24 17:17","pubTimestamp":1758705465,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日天宇股份发生大宗交易，交易数据如下：大宗交易成交价格20.48元，相对当日收盘价折价21.44%，成交236.62万股，成交金额4846.07万元，买方营业部为机构专用，卖方营业部为浙商证券股份有限公司台州环城东路证券营业部。近三个月该股共发生2笔大宗交易，合计成交2.87万手，折价成交2笔。截至2025年9月24日收盘，天宇股份报收于26.07元，上涨1.84%，换手率1.07%，成交量2.26万手，成交额5860.54万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092400029815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2567135301","title":"天宇股份（300702）股东屠勇军质押1000万股，占总股本2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567135301","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567135301?lang=zh_cn&edition=full","pubTime":"2025-09-15 18:28","pubTimestamp":1757932110,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份9月15日公开信息显示，股东屠勇军向中国银河证券股份有限公司合计质押1000.0万股，占总股本2.87%。质押详情见下表：截止本公告日，股东林洁已累计质押股份2863.6万股，占其持股总数的23.47%，股东屠勇军已累计质押股份2780.0万股，占其持股总数的48.68%。天宇股份主营业务：化学原料药及中间体的研发、注册、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500026454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2564632453","title":"天宇股份(300702.SZ)：坎地沙坦酯片完成药品注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2564632453","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564632453?lang=zh_cn&edition=full","pubTime":"2025-09-04 16:09","pubTimestamp":1756973365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天宇股份(300702.SZ)公告，公司全资子公司浙江诺得药业有限公司(简称“诺得药业”)于近日收到国家药品监督管理局核准签发的关于坎地沙坦酯片的《药品注册证书》。坎地沙坦酯片适用于原发性高血压。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2564598890","title":"9月1日天宇股份涨6.08%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564598890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564598890?lang=zh_cn&edition=full","pubTime":"2025-09-01 16:29","pubTimestamp":1756715379,"startTime":"0","endTime":"0","summary":"证券之星消息，9月1日天宇股份涨6.08%，收盘报28.44元，换手率6.29%，成交量13.29万手，成交额3.74亿元。重仓天宇股份的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。该公募基金现任基金经理为陈旭。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100021310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2563235110","title":"天宇股份最新公告：子公司制剂产品首次获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2563235110","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563235110?lang=zh_cn&edition=full","pubTime":"2025-08-29 20:21","pubTimestamp":1756470088,"startTime":"0","endTime":"0","summary":"天宇股份公告称，公司全资子公司诺得药业向美国FDA申报的奥美沙坦酯氢氯噻嗪片的新药简略申请已获得批准。该药品主要用于治疗高血压，由Cosette Pharmaceuticals, Inc研发，于2003年6月在美国上市。诺得药业该药品于2020年2月获得美国FDA受理，截至目前累计研发投入约762.77万元。公司产品奥美沙坦酯氢氯噻嗪片成功获得美国FDA上市批准，是制剂产品首次获得美国FDA批准，标志着公司制剂产品正式取得美国市场准入资格，进一步深化了海外业务布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900041786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2562271816","title":"【机构调研记录】凯石基金调研天宇股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2562271816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562271816?lang=zh_cn&edition=full","pubTime":"2025-08-26 08:01","pubTimestamp":1756166507,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月25日披露的机构调研信息，凯石基金近期对1家上市公司进行了调研，相关名单如下：1）天宇股份 调研纪要：报告期内，天宇股份各业务板块毛利率同比环比均提升，主要得益于规模效应和降本增效。凯石基金成立于2017年，截至目前，资产管理规模1.06亿元，排名203/210；资产管理规模1.06亿元，排名175/210；管理公募基金数7只，排名163/210；旗下公募基金经理4人，排名156/210。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082600009902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768226152057,"stockEarnings":[{"period":"1week","weight":0.0784},{"period":"1month","weight":0.0362},{"period":"3month","weight":-0.0136},{"period":"6month","weight":-0.0093},{"period":"1year","weight":0.5918},{"period":"ytd","weight":0.0784}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江天宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15238人(较上一季度减少8.06%)","perCapita":"13857股","listingDate":"2017-09-19","address":"浙江省台州市黄岩区黄岩江口化工开发区","registeredCapital":"34797万元","survey":" 浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。","listedPrice":22.41},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天宇股份,300702,天宇股份股票,天宇股份股票老虎,天宇股份股票老虎国际,天宇股份行情,天宇股份股票行情,天宇股份股价,天宇股份股市,天宇股份股票价格,天宇股份股票交易,天宇股份股票购买,天宇股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}